Sandoz Group Earnings Call Highlights Biosimilar-Fueled Surge

Sandoz Group Ltd Sponsored ADR ((SDZNY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Sandoz Group Ltd’s latest earnings call struck an upbeat tone as management highlighted record sales, expanding margins and strong cash generation despite a handful of notable headwinds. Executives framed 2025 as a year where biosimilars, disciplined costs and strategic investment outweighed pressures from price erosion, FX and regulatory complexity.

Record Revenue Milestone Above $11 Billion

Net sales surpassed $11.0 billion for the first time, reaching $11.1 billion and growing around 5% in constant currencies, with underlying growth cited at 6%. The fourth quarter extended Sandoz’s streak to 17 consecutive quarters of sales growth, underlining the resilience of its diversified generics and biosimilars portfolio.

Biosimilars Drive Growth and Margin Mix

Biosimilars were the clear growth engine, rising between 13% and 18% on an underlying basis and now making up roughly 30% of total sales, or 31% in Q4. Management emphasized that this shift toward higher-value biologics has materially improved the company’s sales mix and is a key driver of margin expansion.

Margin Expansion and Profitability Strength

Core EBITDA margin increased by 160 basis points to 21.7%, up from 20.1% a year earlier, helped by scale and mix benefits from biosimilars. Core EBITDA itself rose about 14% year on year, while core gross profit reached $5.6 billion, translating into a robust gross margin of 50.6%.

EPS Acceleration and Robust Cash Generation

Core diluted EPS jumped 33%, reflecting both higher operating profit and financial discipline. Management free cash flow climbed by $435 million to $1.5 billion, supported by stronger earnings and tighter working capital management, giving Sandoz more flexibility for investment and shareholder returns.

Improved Returns and Healthier Balance Sheet

Core return on invested capital improved to 14.5%, an increase of roughly 2.0 to 2.2 percentage points, signaling better efficiency in deploying capital. Net debt to core EBITDA fell to about 1.5 times, and while reported net debt stood at $3.6 billion due to FX, underlying net debt dropped by $200 million to roughly $3.1 billion.

Launch Momentum Across Key Biosimilar Franchises

Sandoz spotlighted a wave of product launches, including Pyzchiva in the U.S. and EU auto injector formats and Tyruko rollouts across Europe and the U.S. The company also launched Wyost and Jubbonti as the first denosumab biosimilars in the U.S., alongside EU and Canada entries, while Afqlir’s European debut and Enzeevu’s expanded label are set to bolster future growth.

Strategic Acquisition and Capacity Expansion

The acquisition of Just-Evotec Biologics Europe, completed at the end of 2025, is intended to deepen Sandoz’s biologics development and continuous manufacturing capabilities. In parallel, the firm is investing heavily to build an end-to-end biosimilars hub in Slovenia, with CapEx around $700 million in 2025 and a peak near $1.1 billion in 2026.

Diversified Geographic Growth and Volume Tailwinds

Growth was broad-based, with Europe representing 54% of sales and expanding about 6%, International markets at roughly 24% of sales with underlying growth of 9% for the year and 14% in Q4, and North America at 22% with 5% underlying growth. Overall sales benefited from an 8% volume uplift and a 2% FX tailwind, partially offset by 3% price erosion.

Sustainability, Access and Health System Savings

Management underscored the company’s impact, noting that Sandoz products served more than 1 billion patients across over 100 countries and generated $26 billion in savings for health systems. The firm also reported emissions cuts of 18% in Scope 1, 15% in Scope 2 and 1% in Scope 3, with science-based targets submitted for external validation.

Penicillin B2B Business Under Price Attack

The penicillin business-to-business segment came under pressure in the second half of 2025 due to aggressive price dumping from Asian active ingredient suppliers, eroding sales value. Management expects these adverse dynamics to continue into the first half of 2026 and cautioned that policy shifts such as India’s minimum import price changes could further distort the market.

Persistent Price Erosion and Competitive Threats

Price erosion remained a structural headwind at roughly 3% in 2025, and Sandoz anticipates continued low- to mid-single-digit declines in 2026. The company also flagged that the denosumab franchise, despite a strong start, will likely face tougher pricing as more competitors enter the market.

FX Distortion on Reported Leverage

A stronger euro and Swiss franc against the U.S. dollar pushed reported net debt up to $3.6 billion, creating an optical drag on leverage metrics. Executives stressed that on a constant-currency basis net debt actually improved to about $3.1 billion, underscoring that the underlying balance sheet is strengthening.

One-Off Charges and SaaS Cost Headwinds

One-off costs were approximately $0.4 billion in 2025 and are expected to decline to about $0.3 billion in 2026, in line with prior guidance of $0.7 billion combined over the two years. In addition, around $50 million of software and IT implementation expenses in 2025, likely to repeat in 2026, cannot be capitalized under SaaS rules and therefore weigh on earnings rather than capex.

Regulatory and IP Uncertainty in the U.S.

Management highlighted that complex patent landscapes in key U.S. originator products introduce significant uncertainty around biosimilar launch timing and potential market size. Historical tactics that extended market exclusivity for reference drugs were cited as examples of why regulatory and IP risk remains a key variable for Sandoz’s U.S. growth trajectory.

Long-Term but Unclear GLP-1 Opportunity

The company framed GLP-1 medicines as an attractive long-term biosimilar opportunity but warned that near-term financial impact is uncertain. Regulatory approval timing, evolving demand patterns and existing supply constraints in markets such as India make it difficult to forecast volumes and shape commercial strategy.

Integration Costs and Legal Frictions

Sandoz expects one-off integration costs tied to the Just-Evotec business in France in 2026, which are built into its outlook and will dampen near-term earnings. Local legal disputes and injunctions in certain markets, including past court-driven interruptions, are viewed as sporadic obstacles but not strategic roadblocks.

Forward-Looking Guidance and Capital Plans

For 2026, Sandoz guided to mid- to high-single-digit net sales growth in constant currencies, with an expected roughly 2 percentage point tailwind from FX and continued low- to mid-single-digit price erosion. Management targets about a 100 basis point uplift in core EBITDA margin versus 2025, while absorbing penicillin B2B pressures in early 2026, acquisition integration costs, peak biosimilar-focused capex near $1.1 billion, around $0.3 billion of one-offs and recurring SaaS implementation expenses.

Sandoz’s earnings call painted the picture of a company firmly on the front foot, leveraging biosimilars, disciplined capital deployment and sustainability credentials to drive profitable growth. While pricing, FX and legal-regulatory risks remain, management’s confident guidance and heavy investment in biologics infrastructure signal a strategy built for durable, long-term value creation.